Isaac Cheng

Insider Reports History

Entity
Individual
Location
C/O Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Isaac Cheng:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Amylyx Pharmaceuticals, Inc. Director Common Stock 10.4M $170M $16.33 Jan 6, 2022 Indirect
Amylyx Pharmaceuticals, Inc. Director Common Stock 6.58K $107K $16.33 Jan 6, 2022 Direct
Amylyx Pharmaceuticals, Inc. Director Stock Option (Right to Buy) 19K Jun 9, 2022 Direct
Amylyx Pharmaceuticals, Inc. Director Series A Preferred Stock 0 Jan 6, 2022 Indirect
Amylyx Pharmaceuticals, Inc. Director Series B Preferred Stock 0 Jan 6, 2022 Indirect
Amylyx Pharmaceuticals, Inc. Director Series C-1 Preferred Stock 0 Jan 6, 2022 Indirect
Amylyx Pharmaceuticals, Inc. Director Series C-2 Preferred Stock 0 Jan 6, 2022 Indirect

Insider Reports Filed by Isaac Cheng

Symbol Company Period Transactions Value $ Form Type Date Filed Role
AMLX Amylyx Pharmaceuticals, Inc. Jun 9, 2022 1 $0 4 Jun 10, 2022 Director
AMLX Amylyx Pharmaceuticals, Inc. Jan 6, 2022 10 $125K 4 Jan 10, 2022 Director
AMLX Amylyx Pharmaceuticals, Inc. Jan 6, 2022 0 $0 3 Jan 6, 2022 Director